Ther Adv Med Oncol

2023, Vol. 15: 1

17588359231201818

© The Author(s), 2023. Article reuse guidelines: sagepub.com/journalspermissions

of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2– early breast cancer

Corrigendum to Rationale and trial design

Slamon DJ, Fasching PA, Hurvitz S, *et al.* Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. *Therapeutic Advances in Medical Oncology.* 2023; 15. doi:10.1177/17588359231178125.

In the original published version of this paper, Figure 3 incorrectly depicted the inclusion criteria for the monarchE trial with respect to patients with Stage III N1 disease. Figure 3 has now been updated to accurately depict the inclusion of patients with Stage III N1 disease in the monarchE trial.

Visit Sage journals online journals.sagepub.com/ home/tam

Sage journals

journals.sagepub.com/home/tam



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Sage and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).